Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Cash & Equivalents (2020 - 2025)

PROCEPT BioRobotics has reported Cash & Equivalents over the past 6 years, most recently at $275.1 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $275.1 million for Q4 2025, down 14.77% from a year ago — trailing twelve months through Dec 2025 was $275.1 million (down 14.77% YoY), and the annual figure for FY2025 was $275.1 million, down 14.77%.
  • Cash & Equivalents for Q4 2025 was $275.1 million at PROCEPT BioRobotics, down from $294.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PRCT hit a ceiling of $322.8 million in Q4 2024 and a floor of $86.1 million in Q1 2021.
  • Median Cash & Equivalents over the past 5 years was $263.5 million (2022), compared with a mean of $245.9 million.
  • Biggest five-year swings in Cash & Equivalents: surged 230.11% in 2022 and later plummeted 44.52% in 2023.
  • PROCEPT BioRobotics' Cash & Equivalents stood at $304.3 million in 2021, then fell by 27.1% to $221.9 million in 2022, then increased by 15.94% to $257.2 million in 2023, then rose by 25.48% to $322.8 million in 2024, then dropped by 14.77% to $275.1 million in 2025.
  • The last three reported values for Cash & Equivalents were $275.1 million (Q4 2025), $294.3 million (Q3 2025), and $302.7 million (Q2 2025) per Business Quant data.